Empreendimentos Pague Menos SA
BOVESPA:PGMN3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Empreendimentos Pague Menos SA
BOVESPA:PGMN3
|
BR |
|
EOG Resources Inc
NYSE:EOG
|
US |
|
NSI NV
AEX:NSI
|
NL |
Empreendimentos Pague Menos SA
Empreendimentos Pague Menos SA engages in the retail of medicine, perfumes, toiletries, beauty products, cosmetics, and skin care products. The company is headquartered in Fortaleza, Ceara and currently employs 25,701 full-time employees. The company went IPO on 2020-09-02. Through a drugstore chain, the Company sells medicines, perfumes, personal care and household products, cosmetics, as well as grocery goods, among others. Additionally, It offers a range of financial services, such as bill collection and credit card issuing. The firm also operates a call center that provides information related to drugs usage.
Empreendimentos Pague Menos SA engages in the retail of medicine, perfumes, toiletries, beauty products, cosmetics, and skin care products. The company is headquartered in Fortaleza, Ceara and currently employs 25,701 full-time employees. The company went IPO on 2020-09-02. Through a drugstore chain, the Company sells medicines, perfumes, personal care and household products, cosmetics, as well as grocery goods, among others. Additionally, It offers a range of financial services, such as bill collection and credit card issuing. The firm also operates a call center that provides information related to drugs usage.
Same-store strength: Same-store sales were reported at ~18.6% YoY (management also referenced 18.3% in remarks), marking five consecutive quarters above 17% and driving market-share gains.
Sales & mix: Revenue grew nearly 20% YoY (management used both “nearly 20%” and 18.3%), with average monthly sales per store at BRL 855,000 and omnichannel representing 21% of sales.
Profitability: EBITDA reached BRL 905 million (EBITDA margin 5.6%), up materially year‑over‑year; net income for the LTM was ~BRL 287 million (management also cited BRL 285 million).
Cash & leverage: Operating cash flow was BRL 474 million (52% conversion of EBITDA); net debt/EBITDA fell to 2.0x from 4.3x two years earlier.
Operational wins: Inventory losses fell 27%, stock days dropped to 103 days (from 112), and ROIC improved to 21%. Popular Pharmacy share doubled to ~4% of sales.
GLP-1 impact: GLP-1 drugs represented about 9% of revenue; management expects continued strong demand and expects similar/generic launches in Brazil (management cited July as timing for initial arrivals).
No guidance change: Management did not provide formal forward guidance or adjust guidance on the call; commentary focused on strategic levers, scaling initiatives and cost/working-capital discipline.
